Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

This is a multicentre, randomized, double-blind, placebo controlled, parallel group study
designed to evaluate the efficacy and safety of tezepelumab in adults and adolescents with
severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma
controller medication with or without OCS. Approximately 1060 subjects will be randomized
globally. Subjects will receive tezepelumab, or placebo, administered via subcutaneous
injection at the study site, over a 52-week treatment period. The study also includes a
post-treatment follow-up period of 12 weeks.

Inclusion Criteria:

- Age. 12-80

- Documented physician-diagnosed asthma for at least 12 months

- Subjects who have received a physician-prescribed asthma controller medication with
medium or high dose ICS for at least 12 months.

- Documented treatment with a total daily dose of either medium or high dose ICS (≥ 500
µg fluticasone propionate dry powder formulation equivalent total daily dose) for at
least 3 months.

- At least one additional maintenance asthma controller medication is required according
to standard practice of care and must be documented for at least 3 months.

- Morning pre-BD FEV1 <80% predicted normal (<90% for subjects 12-17 yrs)

- Evidence of asthma as documented by either: Documented historical reversibility of
FEV1 ≥12% and ≥200 mL in the previous 12 months OR Post-BD (albuterol/salbutamol)
reversibility of FEV1 ≥12% and ≥200 mL during screening.

- Documented history of at least 2 asthma exacerbation events within 12 months.

- ACQ-6 score ≥1.5 at screening and on day of randomization

Exclusion Criteria:

- Pulmonary disease other than asthma.

- History of cancer.

- History of a clinically significant infection.

- Current smokers or subjects with smoking history ≥10 pack-yrs.

- History of chronic alcohol or drug abuse within 12 months.

- Hepatitis B, C or HIV.

- Pregnant or breastfeeding.

- History of anaphylaxis following any biologic therapy.

- Subject randomized in the current study or previous tezepelumab studies.